Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates.

More search options...

Chin, MKY; Hsia, Y; Goossens, H; Versporten, A; Bielicki, J; Sharland, M; Donà, D (2020) Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates. Pediatr Infect Dis J, 39 (11). pp. 1032-1034. ISSN 1532-0987 https://doi.org/10.1097/INF.0000000000002847
SGUL Authors: Hsia, Yingfen

Preview

PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].
Download (1MB) | Preview

Abstract

Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations.

Item Type:

Article

Additional Information:

This is a non-final version of an article published in final form in Chin, MKY; Hsia, Y; Goossens, H; Versporten, A; Bielicki, J; Sharland, M; Donà, D (2020) Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates. Pediatr Infect Dis J, 39 (11). pp. 1032-1034.

Keywords:

Pediatrics, 1114 Paediatrics and Reproductive Medicine

SGUL Research Institute / Research Centre:

Academic Structure > Infection and Immunity Research Institute (INII)

Journal or Publication Title:

Pediatr Infect Dis J

ISSN:

1532-0987

Language:

eng

Dates: